Inventiva Announces That Its IND Application for the Phase II Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2D Has Been Accepted by the FDA

Inventiva announced that the US FDA has completed its safety review of the IND application and concluded that the proof-of-concept Phase II combination trial, with its lead drug candidate lanifibranor and the SGLT2 inhibitor empagliflozin1 in patients with Type 2 Diabetes (T2D) and non-cirrhotic non-alcoholic steatohepatitis (NASH), may proceed.